Virbac SA (VIRP.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

VIRP.PA · Stock Price

EUR 370.00+64.00 (+20.92%)

Market Cap: $3.7B

Historical price data

Market Cap: $3.7BPatents: 20Founded: 1968Employees: 5000+HQ: Carros, France

Overview

Virbac SA is a mission-driven, independent leader in the global animal health market, focused on delivering practical and innovative health solutions for veterinarians, farmers, and pet owners. Founded in 1968, it has grown into the world's sixth-largest veterinary drug manufacturer, achieving €1.465 billion in 2025 sales with a robust 7.9% organic growth rate. Its strategy is built on a diversified portfolio across pharmaceuticals, vaccines, and nutrition, sustained R&D investment, and a strong ESG profile, all underpinned by a founding-family-controlled governance that ensures long-term vision and cultural consistency.

Companion Animal HealthLivestock Animal Health

Technology Platform

An integrated, multi-modal platform encompassing small-molecule pharmaceuticals, biologicals & vaccines, nutritional solutions, and digital diagnostics, focused on practical innovation for veterinary medicine.

Opportunities

Virbac is poised to capitalize on the powerful macro trends of pet humanization, rising global demand for animal protein, and the shift toward preventive care and antimicrobial stewardship in livestock.

Its global footprint provides a direct channel to high-growth emerging markets.

Risk Factors

Key risks include intense competition from larger, better-resourced rivals, regulatory hurdles and changes (especially concerning antibiotic use), exposure to macroeconomic cycles affecting the farm animal segment, and potential supply chain disruptions across its global operations.

Competitive Landscape

Virbac competes with animal health giants like Zoetis, Merck Animal Health, Elanco, and Boehringer Ingelheim. Its primary competitive advantages are its independence from a human pharma parent, allowing for focused agility, and its founder-led, long-term oriented culture that prioritizes pure animal health innovation.

More companies in France →